Status:
COMPLETED
TEG Anticoagulation Monitoring During ECMO
Lead Sponsor:
Policlinico Hospital
Collaborating Sponsors:
The Mediterranean Institute for Transplantation and Advanced Specialized Therapies
Conditions:
Extracorporeal Membrane Oxygenation Complication
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The best anticoagulation strategy during Extracorporeal Membrane Oxygenation (ECMO) is unknown. Actual recommendations suggest to use unfractionated heparin infusion and monitor the effect with either...
Detailed Description
Extracorporeal membrane oxygenation (ECMO) is frequently used as a supportive tool in the settings of acute severe respiratory and/or circulatory failure. The presence of the extracorporeal circuit an...
Eligibility Criteria
Inclusion
- All patients that initiate ECMO support for acute respiratory failure at our centre or by our equipe at another centre will be screened for eligibility.
Exclusion
- Patients under the age of 18, with proven Heparin-induced Thrombocytopenia or with a platelets count of less than 30.000/mm3 will be excluded from the study.
Key Trial Info
Start Date :
September 2 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 30 2016
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT02271126
Start Date
September 2 2014
End Date
November 30 2016
Last Update
July 5 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fondazione IRCCS Cà Granda - Ospedale Maggiore Policlinico
Milan, Lombardy, Italy, 20131